Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02208375 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02208375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02208375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 11, 2014
Completion date
June 30, 2028
Enrollment
159 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 mutation carrier, brca2 mutation carrier, endometrial adenocarcinoma, estrogen receptor negative, her2/neu negative, high grade ovarian serous adenocarcinoma, progesterone receptor negative, recurrent breast carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent uterine corpus carcinoma, stage iii uterine corpus cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, stage iv uterine corpus cancer ajcc v7, triple-negative breast carcinoma